Functional psychoses: Molecular-genetic evidence for a continuum

The Overlap of Affective and Schizophrenic Spectra

Volumn 9780521858588, Issue , 2006, Pages 55-78

  Stassen, Hans H ^a   Scharfetter, Christian ^a   Angst, Jules ^a  

^a Psychiatrische Universität sklinik Zürich   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CATCHMENTS; CURRICULA; DEVELOPING COUNTRIES; DIAGNOSIS;

BIPOLAR ILLNESS; CLINICAL SYNDROMES; DEVELOPED COUNTRIES; EPIDEMIOLOGIC-STUDY; GENERAL POPULATION; MENTAL DISORDERS; MOLECULAR GENETICS; WORLD HEALTH ORGANIZATION;

DISEASES;

EID: 39649083246     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544040.005     Document Type: Chapter

References (101)

1. Agid, O., Kapur, S., Arenovich, T. and Zipursky, R. B. (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry, 60(12), 1228–35.
2. Aguilar, M. C., Gurpegui, M., Diaz, F. J. and de Leon, J. (2005). Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions British Journal of Psychiatry, 186, 215–21.
3. Angst, J., Scharfetter, C., Stassen, H. H. and Winokur, G. (1988). Schedule for Affective Disorders and Schizophrenia (SADS): Syndrome Checklists SSCL-16 and Supplement. Psychiatric University Hospital Zurich (available on request from http://www.bli.unizh.ch/BLI/Subhome/frboegen.html).
4. Angst, J. and Stassen, H. H. (2001). Do antidepressants really taken several weeks to show effect? In Antidepressants, ed. B. E. Leonard. Basel: Birkhäuser, pp. 21–30.
5. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders DSM-IV. Washington, DC: American Psychiatric Association.
6. Ascari-Raccagni, A., Baldari, U., Rossi, E. and Alessandrini, F. (2000). Exacerbation of chronic large-plaque psoriasis associated with olanzepine therapy. Journal of the European Academy of Dermatology and Venereology, 14, 315–16.
7. Audrain-McGovern, J., Lerman, C., Wileyto, E. P., Rodriguez, D. and Shields, P. G. (2004). Interacting effects of genetic predisposition and depression on adolescent smoking progression. American Journal of Psychiatry, 161(7), 12224–30.
8. Bailer, U., Leisch, F., Meszaros, K. et al. (2002). Genome scan for susceptibility loci for schizoprenia and bipolar disorder. Biological Psychiatry, 52 (1), 40–52.
9. Baumann, P., Hiemke, C., Ulrich, S. et al. (2004). Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Therapeutic Drug Monitoring, 26(2), 167–70.
10. Berrettini, W. H. (2000). Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biological Psychiatry, 48(6), 531–8.
11. Boyd, J. H., Burke, J. D., Gruenberg, E. et al. (1984). Exclusion criteria of DSM-III. A study of co-occurrence of hierarchy-free syndromes. Archives of General Psychiatry, 41, (10), 983–9.
12. Brockmöller, J., Kirchheiner, J., Schmider, J. et al. (2002). The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. International Journal of Clinical Pharmacology and Therapeutics, 72(4), 438–52.
13. Bukstein, O. G., Brent, D. A. and Kaminer, Y. (1989). Comorbidity of substance abuse and other psychiatric disorders in adolescents. American Journal of Psychiatry, 146(9), 1131–41.
14. Burghes, A. H., Vaessin, H. E. and Chapelle de la, A. (2001). The land between Mendelian and multifactorial inheritance. Science, 293, 2213–14.
15. Cadoret, R. J. (1978). Evidence for genetic inheritance of primary affective disorder in adoptees. American Journal of Psychiatry, 135 (4), 463–6.
16. Cadoret, R. J., O’Gorman, T.W., Heywood, E. and Troughton, E. (1985). Genetic and environmental factors in major depression. Journal of Affective Disorders, 9(2), 155–64.
17. Cassano, G. B., Pini, S., Saettoni, M., Rucci, P. and Dell’Osso, L. (1998). Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. Journal of Clinical Psychiatry, 59(2), 60–8.
18. Ciusani, E., Zullino, D. F., Eap, C. B. et al. (2004). Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. Journal of Psychopharmacology, 18(4), 559–66.
19. Collins-Schramm, H. E., Kittles, R. A., Operario, D. J. et al.(2002). Markers that discriminate between European and African ancestry show limited variation within Africa. Human Genetics, 111, 566–9.
20. Correll, C. U. and Malhotra, A. K. (2004). Pharmacogenetics and antipsychotic-induced weight gain. Psychopharmacology, 174 (4), 477–89.
21. Craddock, N., O’Donovan M. C. and Owen M. J. (2005). The genetics of schizophrenia and bipolar disorder: dissecting psychosis. American Journal of Medical Genetics, 42(3), 193–204.
22. DeLeon, J., Becona, E., Gurpegui, M., Gonzalez-Pinto, A. and Diaz, F. J. (2002). The association between high nicotine dependence and severe mental illness may be consistent across countries, Journal of Clinical Psychiatry, 63(9), 812–16.
23. DeLeon, J. and Diaz, F. J. (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizoprenia Research, 76(2–3), 135–57.
24. DeLuca, V., Wong, A. H., Müller, D. J. et al.(2004). Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology, 29(8), 1522–6.
25. DeMilio, L. (1989). Psychiatric syndromes in adolescent substance abusers. American Journal of Psychiatry, 146(9), 1212–14.
26. Etter, M., Mohr, S., Garin, C. and Etter, J. F. (2004). Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population. Schizophrenia Bulletin, 30(2), 459–68.
27. Faraone, S. V., Kremen, W. S., Lyons, M. J. et al.(1995). Diagnostic accuracy and linkage analysis: how useful are schizophrenia spectrum phenotypes? American Journal of Psychiatry, 152, 1286–90.
28. Faraone, S.V., Su, J., Taylor, L. et al. (2004b). A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families. Human Heredity, 57(2), 59–68.
29. Faraone, S. V., Su, J. and Tsuang, M. T. (2004a). A genome-wide scan of symptom dimensions in bipolar disorder pedigrees of adult probands. Journal of Affective Disorders, 82 Suppl. 1, S71–8.
30. Fergusson, D. M., Goodwin, R. D. and Horwood, L. J. (2003). Major depression and cigarette smoking: results of a 21-year longitudinal study. Psychological Medicine, 33(8), 1357–67.
31. Freedman, R., Olincy, A., Ross, R. G. et al. (2003). The genetics of sensory gating deficits in schizophrenia. Current Psychiatry Reports, 5(2), 155–61.
32. Gault, J., Hopkins, J., Berger, R. et al.(2003). Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects. American Journal of Medical Genetics, 123 B(1), 39–49.
33. Glatt, S. J., Faraone, S. V. and Tsuang, M. T. (2003). CAG-repeat length in exon 1 of KCNN3 does not influence risk for schizophrenia or bipolar disorder: a meta-analysis of association studies. American Journal of Medical Genetics, 121 B(1), 14–20.
34. Gottesman, I. I. and Bertelsen, A. (1989). Confirming unexpressed genotypes for schizophrenia. Risks in the offspring of Fischer’s Danish identical and fraternal discordant twins. Archives of General Psychiatry, 46(10), 867–72.
35. Gottesman, I. I. and Shields, J. (1977). Contributions of twin studies to perspectives on schizophrenia. In: Maher B.A. (ed) Contributions to the Psychopathology of Schizophrenia. New York: Academic Press, pp. 169–266.
36. Grasmader, K., Verwohlt, P. L., Rietschel, M. et al. (2004). Impact of polymorphisms of cytochrome-P560 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. European Journal of Clinical Pharmacology, 60(5), 329–36.
37. Guptaa, M. A. and Guptat, A. K. (2001). The use of antidepressant drugs in dermatology. Journal of the European Academy of Dermatology and Venereology, 15, 512–18.
38. Heston L. L. (1966). Psychiatric disorders in foster home reared children of schizophrenic mothers. British Journal of Psychiatry, 112, 819–25.
39. Hoffmann, K., Stassen, H. H. and Reis, A. (2000). Genkartierung in Isolatpopulationen. Medizinische Genetik¸12 (4), 428–37.
40. Jablensky, A., Sartorius, N., Ernberg, G. et al. (1992). Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine Monograph Suppl. 20, 1–97.
41. Keitner, G. I., Ryan, C. E., Miller, I. W., Kohn, R. and Epstein, N. B. (1991). 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). American Journal of Psychiatry, 148 (3), 345–50.
42. Kendler, K. S. (2003). The genetics of schizophrenia: chromosomal deletions, attentional disturbances, and spectrum boundaries. American Journal of Psychiatry, 160(9), 1549–53.
43. Kendler, K. S., Masterson, C. C. and Davis, K. L. (1985). Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia, and medical illness. British Journal of Psychiatry, 147, 524–31.
44. Kessler, R. C., McGonagle, K. A., Zhao, S. et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 51(1), 8–19.
45. Kety, S. S. (1978). Schizophrenic illness in the families of schizophrenic adoptees: Findings from the Danish national sample. Schizophrenia Bulletin, 14, 217–22.
46. Kety, S. S., Rosenthal, D., Wender, P. H. and Schulsinger, F. (1971). Mental illness in the biological and adoptive families of adopted schizophrenics. American Journal of Psychiatry, 128(3), 302–6.
47. Khan, A., Khan, S. and Brown, W. A. (2002). Are placebo controls necessary to test new antidepressants and anxiolytics? International Journal of Neuropsychopharmacology, 5(3), 193–7.
48. Khan, A., Khan, S. R., Leventhal, R. M. and Brown, W. A. (2001a). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Interantional Journal of Neuropsychopharmacology, 4(2), 113–18.
49. Khan, A., Khan, S. R., Leventhal, R. M. and Brown, W. A. (2001b). Symptom reduction and sucide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. American Journal of Psychiatry, 158(9), 1449–54.
50. Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M. L., Licinio, J., Roots, I. and Brockmoller, J. (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 9(5), 442–73.
51. Leonard, S., Adler, L. E., Benhammou, K. et al. (2001). Smoking and mental illness. Pharmacology Biochemistry & Behavior, 70(4), 561–70.
52. Leonard, S., Gault, J., Adams, C., Breese, C. R., Rollins, Y., Adler, L. E., Olincy, A. and Freedman, R. (1998). Nicotinic receptors, smoking and schizophrenia. Restorative Neurology and Neuroscience, 12(2–3), 195–201.
53. Leonard, S., Gault, J., Hopkins, J. et al. (2002). Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia Archives of Generla Psychiatry, 59(12), 1085–96.
54. Leff, J., Sartorious, N., Jablensky, A., Korten, A. and Ernberg, G. (1992). The International Pilot Study of Schizophrenia: five-year follow-up findings. Psychological Medicine, 22(1), 131–45.
55. Loftus, J., DeLisi, L. E. and Crow, T. J. (1998). Familial associations of subsyndromes of psychosis in affected sibling pairs with schizophrenia and schizoaffective disorder. Psychiatry Research, 80(2), 101–11.
56. Lyons, M. J., Bar, J. L., Kremen, W. S. et al. (2002). Nicotine and familial vulnerabiligy to schizophrenia; a discordant twin study. Journal of Abnormal Psychology, 111(4), 687–93.
57. Maier, W., Hofgen B., Zobel, A. and Rietschel M. (2005). Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes? European Archives of Psychiatry and Clinical Neuroscience, 255(3), 159–66.
58. Maier, W., Lichtermann, D., Miges, J. et al. (1993). Continuity and discontinuity of affective disorders and schizophrenia. Archives of General Psychiatry, 50, 871–83.
59. Maier, W., Rietschel, M., Lichtermann, D. and Wildenauer, D. B. (1999). Family and genetic studies on the relationship of schizophrenia to affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 249 Suppl. 4, 57–61.
60. Maziade, M., Roy, M. A., Martinez, M. et al. (1995). Negative psychosis and disorganized dimensions in patients with familial schizophrenia or bipolar disorder: continuity and discontinuity between the major psychoses. American Journal of Psychiatry, 152, 1458–63.
61. Maziade, M., Roy, M. A., Rouillard, E. et al. (2001). A search for specific and common susceptibility loci for schizophrenia and bipolar disorder: a linkage study in 13 target chromosomes. Molecular Psychiatry, 6(6), 684–93.
62. McCrone, P., Thornicroft, G., Parkman, S., Nathaniel-James, D. and Ojurongbe, W. (1998). Predictors of mental health service costs for representative cases of psychosis in south London. Psychological Medicine, 28(1), 159–64.
63. McGuire, T. G. (1991). Measuring the economic costs of schizophrenia. Schizophrenia Bulletin, 17(3), 375–88.
64. Mendlewicz, J. and Rainer, J. D. (1977). Adoption study supporting genetic transmission in manic-depressive illness. Nature, 268(5618), 327–9.
65. Miyaoka, T., Seno, H., Inagaki, T. et al. (2000). Schizophrenia associated with psoriasis vulgaris: three case reports. Schizophrenia Research, 41, 383–6.
66. Müller, D. J., Schulze, T. G., Macciardi, F. et al. (2002). Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry, 35(4), 157–8.
67. Nurnberger, J. I., Blehar, M. C., Kaufmann, C. A. et al.(1994). Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Archives of General Psychiatry, 51(11), 849–59.
68. O’Donovan, M. C., Williams, N. M. and Owen, M. J. (2003). Recent advances in the genetics of schizophrenia. Human Molecular Genetics, 12 Suppl. 2, R125–33.
69. Parker, G. (1996). On brightening up: triggers and trajectories to recovery from depression. British Journal of Psychiatry, 168, 263–4.
70. Poirier, M. F., Canceil, O., Bayle, F. et al. (2002). Prevalence of smoking in psychiatric patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26(3), 529–37.
71. Pulver, A. E., Mulle, J., Nestadt, G. et al. (2000). Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes. Molecular Psychiatry, 5(6), 650–3.
72. Rabinowitz, J., Bromet, E. J., Lavelle, J. et al.(1998). Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine, 28(6), 1411–19.
73. Ripoll, N., Bronnec, M. and Bourin, M. (2004). Nicotinic receptors and schizophrenia. Current Medical Research and Opinion, 20(7), 1057–74.
74. Scharfetter, C., Ernst, C., Guggenbühl, s. and Stassen, H. H. (1999). Syndrome-oriented approaches to resolving phenotypic heterogeneity in functional psychoses. Molecular Psychiatry, 4, Suppl. 1, 27.
75. Scharfetter, C. and Stassen, H. H. (1995). Psychopathological concepts. Psychopathology, 28, Suppl. 1, 8–12.
76. Schurhoff, F., Szoke, A., Meary, A. et al. (2003). Familial aggregation of delusional proneness in schizophrenia and bipolar pedigrees. American Journal of Psychiatry, 160(7), 1313–19.
77. Simosky, J. K., Stevens, K. E. and Freedman, R. (2002). Nicotinic agonists and psychosis. Current Drug Targets – CNS and Neurological Disorders, 1(2), 149–62.
78. Stassen, H. H. and Angst, J. (1998). Delayed onset of action of antidepressants: fact or fiction? CNS Drugs, 9(3), 177–84.
79. Stassen, H. H. and Angst, J. (2002). Wirkung und Wirkungseintritt in der Antidepressiva-Behandlung. In Therapie der affektiven Störungen, ed. H. Böker and D. Hell. Stuttgart, New York: Schattauer, pp. 141–65.
80. Stassen, H. H., Begleiter, H., Beirut, L. et al. (2004b). Oligogenic approaches to the predisposition of alcohol dependence. A genome-wide search on 255 families. Neurological Psychiatry & Brain Research, 11, 13–22.
81. Stassen, H. H., Begleiter, H., Porjesz, B. et al. (1999b). Structural decomposition of genetic diversity in families with alcohol dependence. In Goldin, L., Amos, C. I., Chase, G. A. et al. (eds.) Genetic Analysis Workshop 11: Analysis of genetic and environmental factors in common diseases. Genetic Epidemiology, 17, Suppl. 325–30.
82. Stassen, H. H., Bridler, R., Hägele, S. et al. (2000). Schizophrenia and smoking: evidence for a common neurobiological basis? American Journal of Medical Genetics – Neuropsychiatric Genetics, 96, 173–7.
83. Stassen, H. H. Bridler, R., Hell, D., Weisbrod, M. and Scharfetter, C. (2004a). Ethnicityindependent genetic basis of functional psychoses. A Genotype-to-phenotype approach. American Journal of Medical Genetics – Neuropsychiatric Genetics, 124, 101–12.
84. Stassen, H. H., Coppola, R., Torrey, E. F. et al. (1999a). EEG differences in monozygotic twins discordant and concordant for schizophrenia. Psychophysiology, 36(1), 109–17.
85. Stassen, H. H., Angst, J. and Delini-Stula, A. (1999c). Fluoxetine versus moclobemide: crosscomparison between the time courses of improvement. Pharmacopsychiatry, 32, 56–60.
86. Stassen, H. H., Hoffmann, K. and Scharfetter, C. (2003). Similarity by state/descent and genetic vector spaces: Analysis of a longitudinal family study. In Almasy, L., Amos, C. I., Bailey-Wilson, J. E. et al. (eds.). Genetic Analysis Workshop 13: Analysis of longitudinal family data for complex diseases and related risk factors. BMC Genetics, 4, S59, 1–6.
87. Stassen, H. H., Ragaz, M. and Reich, T. (1997). Age-of-onset or age-cohort changes in the lifetime occurrence of depression? Psychiatiatric Genetics, 7, 27–34.
88. Stassen, H. H., Scharfetter, C., Winokur, G. and Angst, J. (1988). Familial syndrome patterns in schizophrenia, schizoaffective disorder, mania, and depression. European Archives of Psychiatry and Clinical Neuroscience, 237, 115–23.
89. Szegedi, A., Muller, M. J., Anghelescu, I. et al. (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. The Journal of Clinical Psychiatry, 64(4), 413–20.
90. Szegedi, A., Rujescu, D., Tadic, A. et al. (2005). The catechol-O-methyltransferase Va1108/158Met-polymorphism affects short-term treatment response to mirtazapine, but not to paroxetien in Major Depression. The Pharmacogenomics Journal, 5(1), 49–53.
91. Tsoh, J. Y., Lam, J. N., Delucchi, K. L. and Hall, S. M. (2003). Smoking and depression in Chinese Americans. American Journal of The Medical Sciences, 326(4), 187–91.
92. Vanable, P. A., Carey, M. P., Carey, K. B. and Maisto, S. A. (2003). Smoking among psychiatric outpatients: relationship to substance use, diagnosis, and illness severity. Psychology of Addictive Behaviors, 17(4), 259–65.
93. Vogt, I. R., Shimron-Abarbanell, D., Neidt, H. et al. (2000). Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and schizophrenia. American Journal of Medical Genetics, 96(2), 217–21.
94. Vuoristo, J. T., Berrettini, W. H., Overhauer, J. et al. (2000). Sequence and genomic organization of the human G-protein Golfalpha gene (GNAL) on chromosome 18p11, a susceptibility region for bipolar disorder and schizophrenia. Molecular Psychiatry, 5(5), 495–501.
95. Weisbrod, M., Hill, H., Sauer, H. et al. (2004). Nongenetic pathologic developments of brainwave patterns in monozygotic twins discordant and concordant for schizophrenia. American Journal of Medical Genetics, 125, 1–9.
96. Weissman, M. M., Leaf, P. J., Tischler, G. L. et al. (1988). Affective disorders in five United States communities. Psychological Medicine, 18(1), 141–53.
97. Wender, P. H., Kety, S. S., Rosenthal, D. et al. (1986). Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Archives of General Psychiatry, 43, 923–9.
98. Wildenauer, D. B., Schwab, S. G., Maier, W. and Detera-Wadleigh, S. D. (1999). Do schizophrenia and affective disorder share susceptibility genes? Schizophrenia Research, 39(2), 107–11.
99. Wolf, R., Wolf, D. and Ruocco, V. (1999). Alcohol intake and psoriasis. Clinics in Dermatology, 17, 423–30.
100. Zubin, J. and Spring, B. (1977). Vulnerability – a new view of schizophrenia. Journal of Abnormal Psychology, 86(2), 103–26.
101. Zubin, J., Magaziner, J. and Steinhauer, S. R. (1983). The metamorphosis of schizophrenia: from chronicity to vulnerability. Psychological Medicine, 13(3), 551–71.